Trials / Unknown
UnknownNCT02787876
Pegteograstim in Children With Solid Tumors
Efficacy and Safety of Pegteograstim on Chemotherapy-induced Neutropenia in Children With Solid Tumors
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors
Detailed description
Children with solid tumor experience neutropenia after cytotoxic chemotherapy, and they usually receive granulocyte colony-stimulating factor (G-CSF) to stimulate neutrophil recovery. However it needs daily injection of G-CSF. Pegteograstim is a new formulation of PEGylated recombinant human G-CSF analogue pegfilgrastim. In this study, investigators aimed to evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegteograstim |
Timeline
- Start date
- 2016-10-04
- Primary completion
- 2018-10-01
- Completion
- 2018-11-01
- First posted
- 2016-06-01
- Last updated
- 2018-09-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02787876. Inclusion in this directory is not an endorsement.